

## PATHOLOGY GRAND ROUNDS



Michael H. A. Roehrl, MD, PhD


Associate Professor of Pathology and Laboratory
Medicine, Weill Cornell Medicine;
Director, Precision Pathology
Memorial Sloan Kettering Cancer Center

# "Proteome-Based Diagnostics: The Next Frontier in Precision Pathology"

Thursday, October 31st, 2019 12:30 p.m.

### Fitkin Amphitheater – LMP 1094

Host: Joanna Gibson, MD, PhD





#### ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### TARGET AUDIENCE

Attending physicians, researchers, house staff, fellows, residents, medical students, nurses.

#### NEEDS ASSESSMENT

Proteome research has transformed the way how we understand health and disease, with a particular focus on the dynamics of signaling and the perturbation by pharmacologic agents. It is now clear that many processes cannot be captured by nucleic-acid-based approaches (genome sequencing, transcriptome), and thus a quantitative analysis of the proteome and its posttranslational modification will afford unique and dy-

namic views into human disease. Pathology is uniquely positioned to champiom proteomics in medical care for diagnosis, risk stratification, therapy guidance, response monitoring, and recurrence detection. Recent advances in mass spectrometry, pre-analytics, and computational data analyses have transformed deep proteome-based diagnostics into a technology that is ready to transform patient care. My talk will highlight specific examples from the lab and their translation into near-clinical use, using examples from Gl cancers and others, and also highlighting our brand new concept of autoantigen-omics in autoimmune disease.

#### LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

• Understand the fundamental technological and computational aspects of proteomics and protogenomics.

- Understand specific applications of proteome-based diagnostics and mass spectrometry in cancer and autoimmunity,
- Understand how proteome-based approaches are transforming the central role of pathology in precision healthcare.

#### **DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)^m. Physicians should only claim credit commensurate with the extent of their participation in the activity.

#### **FACULTY DISCLOSURES**

Speaker Name: — Michael H.A. Roehrl, MD, PhD - Proscia, Trans-Hit; Janssen; Gerson Lehrman Group Course Directors: Manju Prasad, MD - NONE Kurt Schalper, MD, PhD - NONE

Pallavi Gopal, MD, PhD - NONE

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.